Please login to the form below

Not currently logged in
Email:
Password:

Abbott restructuring drags down Q2 profits

But Humira leads sales growth as company prepares to split into two businesses

Abbott headquarters

Restructuring charges and costs related to Abbott's ongoing efforts to split itself into two separate companies dragged its second quarter net profits down by 11 per cent, despite a slight increase in sales.

The US firm announced in October, 2011, that it was planning to spin out its pharmaceuticals business as a distinct company named AbbVie, while its diversified medical products, such as generic medicines and medical devices, would be part of a separate organisation retaining the Abbott name.

Related overheads, in addition to more general restructuring costs, meant the company saw over $218m wiped off its net earnings after tax, where Abbott recorded $1.94bn for the second quarter of 2012 on the back of sales that rose 2 per cent to $9.81bn.

Abbott's soon-to-be-renamed global pharmaceuticals division had superior growth to the company overall, and climbed by 3.9 per cent, helped by increased sales for such products as arthritis treatment Humira (adalimumab), which was up 16.5 per cent $2.33bn, and testosterone gel Androgel, which grew 24.7 per cent to $276m.

Humira is not only Abbott's top-selling product, it is also among the world's top-selling drugs. However, it set to soon face stiff competition from rival arthritis products such as a new patient-friendly version of Roche's RoActemra (tocilizumab) and Pfizer's oral treatment tofacitinib.

The success of Abbott's new pharmaceuticals-focused company will depend largely on how Humira fairs against these competitors once they reach market, although a recent positive decision in Europe for its use in patients with non-radiographic axial spondyloarthritis has put the drug on course to expand its reach.

19th July 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Liberation Unlimited

'Progressive', 'cutting edge' – words used to describe Liberation Unlimited. We believe looking forward is essential to delivering successful and...

Latest intelligence

Growing influence of pharmacists in the sale of Rx and OTC medicines
Find out how the changes within pharmacy have affected their influence over the sales of RX and OTC medicines in this whitepaper....
Drivers of 2014′s Soaring Drug Approvals
The FDA & EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future...
Russian innovation at the crossroads
Despite improvements, investors face rising risks...